Kadimastem Ltd Total Liabilities

Latest as of June 2025: ILA52.41 Million ILA ≈ $140.50K USD

Kadimastem Ltd total liabilities. Based on the latest financial reports, Kadimastem Ltd (KDST) has total liabilities worth ILA52.41 Million ILA (≈ $140.50K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kadimastem Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Kadimastem Ltd (2010–2024)

Total liabilities of Kadimastem Ltd from 2010 to 2024. This chart illustrates how Kadimastem Ltd's total liabilities have evolved over time, based on quarterly financial data.

Kadimastem Ltd Competitors by Total Liabilities

The table below lists competitors of Kadimastem Ltd ranked by their total liabilities.

Company Country Total Liabilities
SUNEX S.A.
WAR:SNX
Poland zł205.21 Million
Hitechpros
PA:ALHIT
France €8.00 Million
Lithium Energy Ltd
AU:LEL
Australia AU$2.64 Million
Renewables Infrastructure Grp
LSE:TRIG
UK GBX2.50 Million
RTA Laboratuvarlari Biyolojik
IS:RTALB
Turkey TL103.51 Million
Data I/O Corporation
NASDAQ:DAIO
USA $6.41 Million
Golden Heaven Group Holdings Ltd. Ordinary Shares
NASDAQ:GDHG
USA $10.80 Million
Innature Bhd
KLSE:5295
Malaysia RM80.33 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Kadimastem Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kadimastem Ltd total assets.

Liquidity & Leverage Metrics

Kadimastem Ltd Total Liabilities Ratios Explained

Kadimastem Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 33.72 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kadimastem Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kadimastem Ltd (2010–2024)

The table below shows the annual total liabilities of Kadimastem Ltd from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 ILA32.44 Million
≈ $86.98K
+154.93%
2023-12-31 ILA12.73 Million
≈ $34.12K
+4.63%
2022-12-31 ILA12.16 Million
≈ $32.61K
+1.70%
2021-12-31 ILA11.96 Million
≈ $32.06K
-36.56%
2020-12-31 ILA18.85 Million
≈ $50.54K
-2.40%
2019-12-31 ILA19.32 Million
≈ $51.78K
+145.18%
2018-12-31 ILA7.88 Million
≈ $21.12K
+0.33%
2017-12-31 ILA7.85 Million
≈ $21.05K
-41.05%
2016-12-31 ILA13.32 Million
≈ $35.71K
+48.97%
2015-12-31 ILA8.94 Million
≈ $23.97K
-14.66%
2014-12-31 ILA10.48 Million
≈ $28.09K
+104.07%
2013-12-31 ILA5.13 Million
≈ $13.76K
-53.76%
2012-12-31 ILA11.10 Million
≈ $29.76K
+39.05%
2011-12-31 ILA7.98 Million
≈ $21.40K
+10.08%
2010-12-31 ILA7.25 Million
≈ $19.45K
--

About Kadimastem Ltd

TA:KDST Israel Biotechnology
Market Cap
$22.18 Million
ILA8.27 Billion ILA
Market Cap Rank
#24647 Global
#353 in Israel
Share Price
ILA2794.00
Change (1 day)
+0.00%
52-Week Range
ILA2794.00 - ILA2794.00
All Time High
ILA78228.15
About

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more